Investigational Drug Study for Multiple Myeloma

Trial ID:
IRB-17-6943
Anuj Mahindra, MD
This study will test the safety of various combinations of an experimental drug called atezolizumab given with current approved drugs daratumumab, lenalidomide, and/or pomalidomide at different dose levels. The purpose is to find out what effects, good or bad, the combination of these drugs has in patients with multiple myeloma that has returned after treatment and does not respond to new treatment, or gets worse within 60 days after finishing the most current therapy.

Patients with multiple myleoma who are planning to undergo Autologous Stem Cell Transplantation may be eligible.

Inclusion Criteria

  • Be 18 years of age or older
  • Be diagnosed with Multiple Myeloma and have received at least one prior line of therapy
  • Be willing and able to undergo bone marrow aspiration and biopsy at the beginning and during the study.

Exclusion Criteria

  • Have had other cancers within 2 years (certain breast, cervical, skin or prostate are allowed).
  • Have cancer pain not able to be controlled by medication.
  • Be pregnant or planning to become pregnant.

Additional Info

  • Atezolizumab and daratumumab are both immunotherapy drugs that may help your immune system stop or reverse the growth of tumors.
  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines.

Contact Info: